Boundless Bio, Inc.
NASDAQ Global SelectTotal Valuation
Boundless Bio, Inc. carries a market capitalization of 55.74M, placing it among publicly traded companies globally. Its enterprise value stands at -19.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 55.74M |
| Enterprise Value | -19.93M |
Share Statistics
Boundless Bio, Inc. currently has 22.41M shares outstanding.
| Shares Outstanding | 22.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.09 |
| P/TBV Ratio | 0.29 |
| P/FCF Ratio | -0.53 |
| P/OCF Ratio | -0.52 |
Financial Position
Boundless Bio, Inc. maintains a current ratio of 9.87, meaning it holds 9.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.87 |
| Quick Ratio | 9.69 |
| Debt / Equity | 55.90 |
| Debt / EBITDA | -0.81 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -33.71 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Boundless Bio, Inc.'s stock has gained approximately 115.65217% over the past 52 weeks. The 50-day moving average sits at 1.84, while the 200-day moving average is 1.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | 115.65217% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 1.39 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -59.47M, while operating income came in at -60.69M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -60.69M |
| Pretax Income | -55.99M |
| Net Income | -55.99M |
| EBITDA | -59.47M |
| EBIT | -60.69M |
| Earnings Per Share (EPS) | -2.50 |
Balance Sheet
Boundless Bio, Inc. holds 92.85M in cash and equivalents against 48.29M in total debt, resulting in a net debt position of -17.48M. Total book value stands at -273.22M, with working capital of 85.03M providing operational flexibility.
| Cash & Cash Equivalents | 92.85M |
| Total Debt | 48.29M |
| Net Debt | -17.48M |
| Equity (Book Value) | -273.22M |
| Book Value Per Share | -12.20 |
| Working Capital | 85.03M |
Cash Flow
Boundless Bio, Inc. produced -47.10M in operating cash flow over the past twelve months. After subtracting -495,000.00 in capital expenditures, free cash flow totaled -47.60M - equivalent to -2.13 per share.
| Operating Cash Flow | -47.10M |
| Capital Expenditures | -495,000.00 |
| Free Cash Flow | -47.60M |
| FCF Per Share | -2.13 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.57 |
| FCF Yield | -189.27 |
Scores
Boundless Bio, Inc. posts an Altman Z-Score of -3.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.14 |